Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 31,346 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study participants Clear all

Conditions: Cardiovascular Diseases, Hyperlipidemias
Interventions: Lipid Challenge, Glucose Challenge, Mixed Meal Challenge; Dietary Supplement
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Amyotrophic Lateral Sclerosis ALS
Interventions: Astaxanthin, Protandim, Melatonin, MitoQ; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Durham, North Carolina • Philadelphia, Pennsylvania

Conditions: Anxiety, COVID-19 Pandemic
Interventions: Mindfulness; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 99 Years
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HIV Infections
Interventions: VH4004280, VH4011499, VH4004280 Matching Placebo, VH4011499 Matching Placebo, Antiretroviral therapy; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Bakersfield, California • DeLand, Florida • Newark, New Jersey

Conditions: Opioid-induced Constipation
Interventions: Methylnaltrexone bromide, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Kidney Stone, Pain, Postoperative, Anxiety Postoperative
Interventions: Meditation; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 12 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Pain
Interventions: Buprenorphine, Placebo; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 4
States / cities: Phoenix, Arizona • Anaheim, California • Pasadena, Maryland + 1 more

Conditions: Interstitial Cystitis
Interventions: LiRIS 400 mg, LiRIS Placebo; Drug · Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 15
States / cities: Glendora, California • Daytona Beach, Florida • Kansas City, Kansas + 12 more

Conditions: Chronic Pain, Fatigue, Substance Use Disorders
Interventions: Not listed
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Kaposi Sarcoma
Interventions: CYT107; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2037
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cervical Spine Herniation
Interventions: MRI-Diffusion Tensor Imaging and Tractrography; Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Parkinson Disease
Interventions: SAGE-217, Levodopa, Antiparkinsonian Agent(s); Drug
Lead sponsor: Biogen; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 11
States / cities: Panorama City, California • Jacksonville, Florida • Miami, Florida + 7 more

Conditions: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases, Overactive Bladder, Urgency Incontinence
Interventions: Solifenacin succinate, Mirabegron, Placebo to match solifenacin succinate, Placebo to match mirabegron; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 3,527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 121
States / cities: Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 96 more

Conditions: Depression Disorders
Interventions: well-being app, List of well-being resources; Device · Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Insomnia, Sleep Disorder
Interventions: SMS Personalized Sleep Intervention; Behavioral
Lead sponsor: University of Missouri, St. Louis; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Opioid-use Disorder
Interventions: Pharmacy-based methadone administration and dispensing; Drug
Lead sponsor: Friends Research Institute, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Raleigh, North Carolina • Zebulon, North Carolina

Conditions: Aging, Fall Injury
Interventions: Medication Action Plan and Patient Empowerment (MAP-PE ); Behavioral
Lead sponsor: University of Iowa; Other
Eligibility: 60 Years to 110 Years
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Clive, Iowa

Conditions: COVID-19
Interventions: Brilacidin, Placebo, Standard of Care (SoC); Drug
Lead sponsor: Innovation Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Winfield, Illinois • Toledo, Ohio

Conditions: Migraine
Interventions: LY3451838, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 9
States / cities: Phoenix, Arizona • Stamford, Connecticut • Ocala, Florida + 6 more

Conditions: Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Interventions: zagociguat 15mg, zagociguat 30mg, Placebo; Drug
Lead sponsor: Tisento Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 10
States / cities: La Jolla, California • Aurora, Colorado • Atlanta, Georgia + 5 more

Conditions: Spinal Cord Injuries (SCI)
Interventions: No Stimulation, Conventional tSCS, Spatiotemporal tSCS; Other · Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 16 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Endometrial Carcinoma, Prostate Carcinoma
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Atopic Dermatitis
Interventions: EDP1815, Placebo; Drug
Lead sponsor: Evelo Biosciences, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 27
States / cities: Birmingham, Alabama • Fountain Valley, California • Fremont, California + 22 more

Search by objective public record fields.

The Mixed Meal Challenge Study

ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments

SMILE: Clinical Trial to Evaluate Mindfulness as Intervention for Racial and Ethnic Populations During COVID-19

Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults

Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures

Meditation Effects on Discomfort, Pain InTerference, and AnxieTy After urEteroscopy

Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain

Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis

Real-world Momentary Assessment of Kratom Use Accompanied by Product Assays: A Natural-history Study for Interdisciplinary Characterization of Kratom Use and Pharmacology

Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)

Diffusion Tensor (Magnetic Resonance) Imaging and Tractography in Herniation of the Cervical Spine

A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease

Chronic Infections and Inflammation in ME/CFS: An Observational Study

This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder

Couples' Affect in Relationships Study

Feasibility of a Personalized SMS Intervention for Insomnia

Opioid Treatment Program (OTP)-Pharmacy Collaboration for Methadone Maintenance Treatment

Medication Empowerment and Deprescription for Safety (MEDS) Study

A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19

A Study of LY3451838 in Participants With Migraine

A Phase 2b Study of Zagociguat in Patients With MELAS

Spatiotemporal tSCS in Spinal Cord Injury

Screening and Staging of Benign vs Malignant Pelvic Abnormalities

A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis